Cybin Inc. (HELP) Stock Price & How to Invest
Last updated July 2026
Short answer
HELP is Cybin Inc., which now does business as Helus Pharma, a clinical-stage biotech developing psychedelic-derived therapies (deuterated psilocybin and DMT analogs) for depression and anxiety. It is a pre-revenue, binary drug-development story whose value rides almost entirely on Phase 3 trial data, not on current earnings.
HELP stock price
As of 2026-07-21, Cybin Inc. (HELP) last closed at $8.29, up 3.2% over the past year. Over the past 52 weeks it has traded between $3.87 and $8.71.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Cybin Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Cybin Inc. (HELP) do?
Cybin Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and adopted the operating name Helus Pharma, is a Toronto-based clinical-stage pharmaceutical company. Its lead program is HLP003 (also referenced as CYB003), a deuterated psilocybin analog being studied as an adjunctive treatment for major depressive disorder in a pivotal Phase 3 program called PARADIGM, which includes the APPROACH and EMBRACE studies. A second candidate, HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. These are neuroactive serotonergic molecules designed to be administered in a supervised clinical setting.
As a pre-revenue biotech, Cybin has essentially no product sales and reports widening net losses as it funds late-stage trials. The company reported cash of roughly $195 million at the end of 2025, giving it a runway measured in quarters rather than years, and it has repeatedly raised equity to extend that runway. The investment picture is therefore binary and event-driven: positive Phase 3 topline data (expected around late 2026) and a clear regulatory path could re-rate the stock sharply, while a trial miss, a financing gap, or heavy dilution could impair it. This is a high-risk, high-variance profile typical of psychedelic-medicine developers.
What's driving Cybin Inc. (HELP)?
1. Phase 3 depression readout
The PARADIGM program (APPROACH plus EMBRACE) testing HLP003 in major depressive disorder is the central catalyst, with topline data anticipated around Q4 2026. A clean efficacy and safety result would be the most material value driver, since MDD is a large addressable market and few psychedelic therapies have reached pivotal-stage data.
2. Anxiety program optionality
HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder with an earlier data readout expected around Q1 2026. Positive signals here would broaden the pipeline beyond a single depression bet and give the platform a second indication.
3. Cash position and financing
Cybin ended 2025 with roughly $195 million in cash, which funds its late-stage trials but implies continued reliance on capital markets. The pace of spending versus milestone timing shapes how much additional dilution shareholders may face before any potential approval.
4. Psychedelic-medicine regulatory path
The broader environment for FDA review of psychedelic and serotonergic therapies is still developing. Clearer agency guidance and precedent from peers could de-risk the category, while setbacks at competing programs could weigh on sentiment across the space.
What are the risks to Cybin Inc. (HELP)?
As a clinical-stage company, Cybin has negligible revenue and posts ongoing net losses, so it depends on trial success and repeated financing to survive. A Phase 3 miss, ambiguous data, or safety signal for HLP003 would be highly damaging given the concentration in a single lead program. Equity raises have diluted existing holders and are likely to continue until the company reaches profitability, which is not forecast in the near term. Regulatory uncertainty around psychedelic therapies, the operational complexity of supervised administration, and competition from other developers add further risk. The stock is volatile and can move sharply on single data points.
How is Cybin Inc. (HELP) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Cybin Inc.'s investor relations page or your broker.
- Share price: ~$5
- Market cap: ~$257M
- Revenue (TTM): ~$0 (pre-revenue, under $1M)
- Cash: ~$195M (end of 2025)
- Net loss (annual): widening, roughly $120M+ cash used
- Shares outstanding: ~50M
Standard earnings multiples do not apply because Cybin has essentially no revenue and runs at a loss while funding Phase 3 trials. Much of its roughly $257 million market value is backed by its cash balance of around $195 million, so the market is assigning only a modest premium for the pipeline ahead of pivotal data. Valuation will hinge on trial outcomes and any resulting financing rather than on current financials.
Who competes with Cybin Inc. (HELP)?
Psychedelic-medicine developers
Companies such as Compass Pathways, atai Life Sciences, and GH Research are pursuing psilocybin, DMT, or related serotonergic therapies for depression and other conditions, competing for the same clinical validation, regulatory precedent, and investor capital.
Novel-mechanism depression and CNS biotechs
Firms advancing new antidepressant and neuropsychiatric mechanisms, including players tied to rapid-acting therapies, compete on the same MDD and anxiety markets that Cybin targets, even where the underlying chemistry differs.
Established neuroscience pharma
Large CNS-focused pharmaceutical companies with approved depression and anxiety franchises hold the commercial and distribution advantages that a clinical-stage entrant like Cybin would need to overcome if its candidates reach the market.
How to invest in Cybin Inc. (HELP)
There are three common ways to get HELP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so HELP sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where HELP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Cybin Inc. (HELP)
HELP is a speculative clinical-stage psychedelic-medicine biotech where the investment case turns on trial readouts and cash runway rather than any existing revenue or profit.
More on Cybin Inc. (HELP)
Whether HELP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HELP a buy?, and where the stock could go from here in the HELP stock forecast.
For income investors, whether HELP pays a dividend and how the payout looks is covered in does HELP pay a dividend?
Build a basket around HELP with Walnut
Use Cybin Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What company is the ticker HELP?
+
HELP is Cybin Inc., a clinical-stage biotech that now operates under the name Helus Pharma. It moved its U.S. listing to the Nasdaq under HELP in early 2026 after previously trading as CYBN on NYSE American.
What does Helus Pharma do?
+
It develops psychedelic-derived neuroactive compounds, including a deuterated psilocybin analog and a deuterated DMT analog, designed as supervised therapies for major depressive disorder and generalized anxiety disorder.
Does HELP have any revenue?
+
No meaningful revenue. Cybin is pre-revenue and reported under $1 million in sales, so it operates at a loss while funding clinical trials, which is typical for a clinical-stage biotech.
What is HELP's lead drug candidate?
+
Its lead candidate is HLP003 (also called CYB003), a deuterated psilocybin analog being tested as an adjunctive treatment for major depressive disorder in the Phase 3 PARADIGM program that includes the APPROACH and EMBRACE studies.
When is the key Phase 3 data expected?
+
Topline data from the pivotal APPROACH study in major depressive disorder has been anticipated around the fourth quarter of 2026, making it the central catalyst for the stock. Timelines can shift with enrollment and analysis.
How much cash does Cybin have?
+
Cybin reported cash of roughly $195 million at the end of 2025. That funds its late-stage trials but, given ongoing losses, the company has repeatedly raised equity to extend its runway.
Why is HELP considered a high-risk stock?
+
Its value depends heavily on binary trial outcomes for a small number of programs, it has no revenue, it burns cash, and it faces dilution and regulatory uncertainty around psychedelic therapies. A single data readout can move the shares sharply.
How does HELP differ from a profitable pharma company?
+
Established pharma companies have approved products, revenue, and earnings, so they trade on financial multiples. HELP is pre-approval and pre-revenue, so it is valued on pipeline potential and cash, not on profits.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Cybin Inc.'s investor relations page or your broker before making investment decisions.